Clinical trial

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

NCT00347919

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention pazopanib (GW786034) 400 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention lapatinib (GW572016) 1500 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention lapatinib (GW572016) 1000 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention pazopanib (GW786034) 800 mg Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-07-01

PhasePHASE2

Conditions

Neoplasms, Breastunresolved

Interventions

pazopanib (GW786034) 400 mgDRUG

lapatinib (GW572016) 1500 mgDRUG

lapatinib (GW572016) 1000 mgDRUG

pazopanib (GW786034) 800 mgDRUG

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Mapped research locations

MoscowRussia3 LondonUnited Kingdom2 BudapestHungary2 Saint PetersburgRussia2 Los AngelesCalifornia, United States1 DallasTexas, United States1 San AntonioTexas, United States1 ParisFrance1 IndianapolisIndiana, United States1 WarsawPoland1 The BronxNew York, United States1 LyonFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00347919 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.